Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Antenatal magnesium sulfate to prevent cerebral palsy|
|Citation:||Archives of Disease in Childhood: Fetal and Neonatal Edition, 2022; 107(2):225-227|
|Amy K Keir, Emily Shepherd, Sarah McIntyre, Alice Rumbold, Charlotte Groves, Caroline Crowther, Emily Joy Callander|
|Abstract:||Magnesium sulfate given to women before birth at <30 weeks’ gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks’ gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.|
|Keywords:||health services research|
|Description:||First published July 7, 2021.|
|Rights:||© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.